查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413217

藥物基因體學市場：按技術、按應用分類 - 2024-2030 年全球預測

Pharmacogenomics Market by Technology (DNA Sequencing, Electrophoresis, Mass Spectrometry), Application (Drug Discovery, Neurology, Oncology) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年藥物基因體學市場規模為84.8億美元，預計2024年將達91億美元，2030年將達到127.3億美元，複合年成長率為5.97%。

藥物基因體學的全球市場

主要市場統計
基準年[2023] 84.8億美元
預測年份 [2024] 91億美元
預測年份 [2030] 127.3億美元
複合年成長率（%） 5.97%
藥物基因組學市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估藥物基因體學市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對藥物基因體學市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-藥物基因體學市場的市場規模和預測是多少？

2-藥物基因體學市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3-藥物基因體學市場的技術趨勢和法律規範是什麼？

4-藥物基因體學市場主要供應商的市場佔有率是多少？

5-進入藥物基因體學市場的適當型態或策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病發生率上升和精準醫療需求
      • 加大醫療基礎建設投資
      • 分子診斷程序相關技術的進步
    • 抑制因素
      • 與研發能力相關的高成本
    • 機會
      • 個人化醫療新趨勢
      • 加強藥物基因體學
    • 任務
      • 缺乏意識和必要的基礎設施
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章藥物基因體學市場：依技術分類

  • DNA序列測定
  • 電泳
  • 質譜
  • 微陣列
  • 聚合酶鍊式反應

第7章藥物基因體學市場：依應用分類

  • 藥物研發
  • 神經病學
  • 腫瘤學
  • 疼痛管理

第8章美洲藥物基因體學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區藥物基因體學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的藥物基因體學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • Admera Health
    • Agena Biosciences Inc.
    • BiogeniQ Inc.
    • CENTOGENE NV
    • Coriell Life Sciences
    • Dynamic DNA Laboratorie
    • Empire Genomics
    • Illunima Inc.
    • Myriad Genetics Inc.
    • OneOme LLC
    • Personalis Inc.
    • Phamatech Inc.
    • Quest Diagnostics
    • Thermo Fisher Scientific Inc.
    • ViennaLab Diagnostics GmbH
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-742BD5183892

[192 Pages Report] The Pharmacogenomics Market size was estimated at USD 8.48 billion in 2023 and expected to reach USD 9.10 billion in 2024, at a CAGR 5.97% to reach USD 12.73 billion by 2030.

Global Pharmacogenomics Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.48 billion
Estimated Year [2024] USD 9.10 billion
Forecast Year [2030] USD 12.73 billion
CAGR (%) 5.97%
Pharmacogenomics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmacogenomics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmacogenomics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmacogenomics Market, highlighting leading vendors and their innovative profiles. These include Admera Health, Agena Biosciences Inc., BiogeniQ Inc., CENTOGENE N.V., Coriell Life Sciences, Dynamic DNA Laboratorie, Empire Genomics, Illunima Inc., Myriad Genetics Inc., OneOme LLC, Personalis Inc., Phamatech Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., and ViennaLab Diagnostics GmbH.

Market Segmentation & Coverage

This research report categorizes the Pharmacogenomics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • DNA Sequencing
    • Electrophoresis
    • Mass Spectrometry
    • Microarray
    • Polymerase Chain Reaction
  • Application
    • Drug Discovery
    • Neurology
    • Oncology
    • Pain Management
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmacogenomics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmacogenomics Market?

3. What are the technology trends and regulatory frameworks in the Pharmacogenomics Market?

4. What is the market share of the leading vendors in the Pharmacogenomics Market?

5. Which modes and strategic moves are suitable for entering the Pharmacogenomics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Pharmacogenomics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of chronic diseases and demand for precision medicine
      • 5.1.1.2. Increasing investments for healthcare infrastructures
      • 5.1.1.3. Technological advancements associated with molecular diagnostics procedure
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development proficiencies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of personalized medicines
      • 5.1.3.2. Rising R&D activities to improve pharmacogenomics
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of awareness and required infrastructural facilities
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Pharmacogenomics Market, by Technology

  • 6.1. Introduction
  • 6.2. DNA Sequencing
  • 6.3. Electrophoresis
  • 6.4. Mass Spectrometry
  • 6.5. Microarray
  • 6.6. Polymerase Chain Reaction

7. Pharmacogenomics Market, by Application

  • 7.1. Introduction
  • 7.2. Drug Discovery
  • 7.3. Neurology
  • 7.4. Oncology
  • 7.5. Pain Management

8. Americas Pharmacogenomics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Pharmacogenomics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Pharmacogenomics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Admera Health
    • 12.1.2. Agena Biosciences Inc.
    • 12.1.3. BiogeniQ Inc.
    • 12.1.4. CENTOGENE N.V.
    • 12.1.5. Coriell Life Sciences
    • 12.1.6. Dynamic DNA Laboratorie
    • 12.1.7. Empire Genomics
    • 12.1.8. Illunima Inc.
    • 12.1.9. Myriad Genetics Inc.
    • 12.1.10. OneOme LLC
    • 12.1.11. Personalis Inc.
    • 12.1.12. Phamatech Inc.
    • 12.1.13. Quest Diagnostics
    • 12.1.14. Thermo Fisher Scientific Inc.
    • 12.1.15. ViennaLab Diagnostics GmbH
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. PHARMACOGENOMICS MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOGENOMICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. PHARMACOGENOMICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PHARMACOGENOMICS MARKET DYNAMICS
  • FIGURE 7. PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOGENOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. PHARMACOGENOMICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOGENOMICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. PHARMACOGENOMICS MARKET SIZE, BY ELECTROPHORESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. PHARMACOGENOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. PHARMACOGENOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. PHARMACOGENOMICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. PHARMACOGENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. PHARMACOGENOMICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. PHARMACOGENOMICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. PHARMACOGENOMICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES PHARMACOGENOMICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM PHARMACOGENOMICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHARMACOGENOMICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 103. PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. PHARMACOGENOMICS MARKET LICENSE & PRICING